Studying Brain Inflammation and White Matter Changes Using Imaging and Blood Tests in Adults with Corticobasal Syndrome

What this Trial Is About

Corticobasal syndrome CBS is a neurodegenerative disorder marked by changes in cognition and behavior, along with movement difficulties such as asymmetric parkinsonism, dystonia, myoclonus, and limb apraxia. This research investigates how inflammation and damage to the brains white matter are related in CBS. The study uses advanced brain imaging and blood plasma markers to explore these processes, comparing CBS patients to those with Alzheimers disease and healthy volunteers. Participants will undergo PET scans using tracers like C-11 ER176 to detect neuroinflammation, and other imaging techniques such as NODDI for white matter structure assessment. Blood samples will measure markers of nerve injury, inflammation, and tau protein. The study also uses beta-amyloid and tau PET scans to categorize CBS patients based on Alzheimers biomarkers. Healthy control data from previous studies will be used for comparison. During the study, participants will be assessed over approximately 4 to 5 years with imaging and blood tests to track inflammation and white matter integrity. Researchers will collect and analyze plasma biomarkers related to neurodegeneration and inflammation. This long-term observation will help clarify the roles of these factors in CBS and its variants, ensuring thorough safety and health monitoring throughout the trial.

Imaging Studies in Corticobasal Syndrome